Low SOX17 expression is a prognostic factor and drives transcriptional dysregulation and esophageal cancer progression

International Journal of Cancer

Volumn 135, Issue 3, 2014, Pages 563-573

  Kuo, I Ying ^a   Wu, Ching Chi ^a   Chang, Jia Ming ^a,b   Huang, Yu Lin ^a   Lin, Chien Hsun ^a   Yan, Jing Jou ^c   Sheu, Bor Shyang ^c   Lu, Pei Jung ^a   Chang, Wei Lun ^c   Lai, Wu Wei ^c   Wang, Yi Ching ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Esophageal squamous cell carcinoma; Prognosis; SOX17; Transcriptional network; Tumor suppressor

Indexed keywords

TRANSCRIPTION FACTOR SOX17;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER GROWTH; CANCER PROGNOSIS; CARCINOGENESIS; CELL GROWTH; CELL MOTILITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CSNK1A1 GENE; DISEASE ACTIVITY; DISEASE ASSOCIATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; FEMALE; FN1 GENE; GENE REPRESSION; GENE TARGETING; HUMAN; MACC1 GENE; MAJOR CLINICAL STUDY; MALAT1 GENE; MALE; MIDDLE AGED; MOLECULAR PATHOLOGY; MOUSE; NBN GENE; NFAT5 GENE; NONHUMAN; ONCOGENE; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; SERBP1 GENE; TRANSCRIPTION REGULATION; TUMOR XENOGRAFT;

ESOPHAGEAL SQUAMOUS CELL CARCINOMA; PROGNOSIS; SOX17; TRANSCRIPTIONAL NETWORK; TUMOR SUPPRESSOR;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL MOVEMENT; CELL PROLIFERATION; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; FEMALE; FIBRONECTINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MICE; MICE, SCID; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROMOTER REGIONS, GENETIC; SOXF TRANSCRIPTION FACTORS; SURVIVAL RATE; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901017307     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28695     Document Type: Article

References (39)

1. Enzinger PC, Mayer RJ,. Esophageal cancer. N Engl J Med 2003; 349: 2241-52.
2. Kamangar F, Dores GM, Anderson WF,. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-50.
3. Guo M, Ren J, House MG, et al. Accumulation of promoter methylation suggests epigenetic progression in squamous cell carcinoma of the esophagus. Clin Cancer Res 2006; 12: 4515-22.
4. Baylin SB, Esteller M, Rountree MR, et al. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 2001; 10: 687-92.
5. Herman JG, Baylin SB,. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349: 2042-54.
6. Tanaka H, Shimada Y, Harada H, et al. Methylation of the 5' CpG island of the FHIT gene is closely associated with transcriptional inactivation in esophageal squamous cell carcinomas. Cancer Res 1998; 58: 3429-34.
7. Xing EP, Nie Y, Song Y, et al. Mechanisms of inactivation of p14ARF, p15INK4b, and p16INK4a genes in human esophageal squamous cell carcinoma. Clin Cancer Res 1999; 5: 2704-13.
8. Si HX, Tsao SW, Lam KY, et al. E-cadherin expression is commonly downregulated by CpG island hypermethylation in esophageal carcinoma cells. Cancer Lett 2001; 173: 71-8.
9. Kuroki T, Trapasso F, Yendamuri S, et al. Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma. Cancer Res 2003; 63: 3724-8.
10. Huang KH, Huang SF, Chen IH, et al. Methylation of RASSF1A, RASSF2A, and HIN-1 is associated with poor outcome after radiotherapy, but not surgery, in oral squamous cell carcinoma. Clin Cancer Res 2009; 15: 4174-80.
11. Zhang W, Glockner SC, Guo M, et al. Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. Cancer Res 2008; 68: 2764-72.
12. Fu DY, Wang ZM, Li C, et al. Sox17, the canonical Wnt antagonist, is epigenetically inactivated by promoter methylation in human breast cancer. Breast Cancer Res Treat 2010; 119: 601-12.
13. Jia Y, Yang Y, Liu S, et al. SOX17 antagonizes WNT/beta-catenin signaling pathway in hepatocellular carcinoma. Epigenetics 2010; 5: 743-9.
14. Hong SM, Omura N, Vincent A, et al. Genome-wide CpG island profiling of intraductal papillary mucinous neoplasms of the pancreas. Clin Cancer Res 2012; 18: 700-12.
15. Chimonidou M, Strati A, Malamos N, et al. SOX17 Promoter methylation in circulating tumor cells and matched cell-free DNA isolated from plasma of patients with breast cancer. Clin Chem 2013; 59: 270-9.
16. Oishi Y, Watanabe Y, Yoshida Y, et al. Hypermethylation of Sox17 gene is useful as a molecular diagnostic application in early gastric cancer. Tumour Biol 2012; 33: 383-93.
17. Katoh M,. Molecular cloning and characterization of human SOX17. Int J Mol Med 2002; 9: 153-7.
18. Sinner D, Rankin S, Lee M, et al. Sox17 and beta-catenin cooperate to regulate the transcription of endodermal genes. Development 2004; 131: 3069-80.
19. Hudson C, Clements D, Friday RV, et al. Xsox17α and-beta mediate endoderm formation in Xenopus. Cell 1997; 91: 397-405.
20. Yasunaga M, Tada S, Torikai-Nishikawa S, et al. Induction and monitoring of definitive and visceral endoderm differentiation of mouse ES cells. Nat Biotechnol 2005; 23: 1542-50.
21. Kanai-Azuma M, Kanai Y, Gad JM, et al. Depletion of definitive gut endoderm in Sox17-null mutant mice. Development 2002; 129: 2367-79.
22. Kim I, Saunders TL, Morrison SJ,. Sox17 dependence distinguishes the transcriptional regulation of fetal from adult hematopoietic stem cells. Cell 2007; 130: 470-83.
23. Chew LJ, Shen W, Ming X, et al. SRY-box containing gene 17 regulates the Wnt/beta-catenin signaling pathway in oligodendrocyte progenitor cells. J Neurosci 2011; 31: 13921-35.
24. Sinner D, Kordich JJ, Spence JR, et al. Sox17 and Sox4 differentially regulate beta-catenin/T-cell factor activity and proliferation of colon carcinoma cells. Mol Cell Biol 2007; 27: 7802-15.
25. Chen YK, Chang WS, Wu IC, et al. Molecular characterization of invasive subpopulations from an esophageal squamous cell carcinoma cell line. Anticancer Res 2010; 30: 727-36.
26. Du YC, Oshima H, Oguma K, et al. Induction and down-regulation of Sox17 and its possible roles during the course of gastrointestinal tumorigenesis. Gastroenterology 2009; 137: 1346-57.
27. Jia Y, Yang Y, Zhan Q, et al. Inhibition of SOX17 by microRNA 141 and methylation activates the WNT signaling pathway in esophageal cancer. J Mol Diagn 2012; 14: 577-85.
28. Stein U, Walther W, Arlt F, et al. MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med 2009; 15: 59-67.
29. Ji P, Diederichs S, Wang W, et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 2003; 22: 8031-41.
30. Yang MH, Chang SY, Chiou SH, et al. Overexpression of NBS1 induces epithelial-mesenchymal transition and co-expression of NBS1 and Snail predicts metastasis of head and neck cancer. Oncogene 2007; 26: 1459-67.
31. Jauliac S, Lopez-Rodriguez C, Shaw LM, et al. The role of NFAT transcription factors in integrin-mediated carcinoma invasion. Nat Cell Biol 2002; 4: 540-4.
32. Panchenko MP, Siddiquee Z, Dombkowski DM, et al. Protein kinase CK1αLS promotes vascular cell proliferation and intimal hyperplasia. Am J Pathol 2010; 177: 1562-72.
33. Wang F, Song G, Liu M, et al. miRNA-1 targets fibronectin1 and suppresses the migration and invasion of the HEp2 laryngeal squamous carcinoma cell line. FEBS Lett 2011; 585: 3263-9.
34. Koensgen D, Mustea A, Klaman I, et al. Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: association with tumor progression. Gynecol Oncol 2007; 107: 266-73.
35. Rosman DS, Phukan S, Huang CC, et al. TGFBR1*6A enhances the migration and invasion of MCF-7 breast cancer cells through RhoA activation. Cancer Res 2008; 68: 1319-28.
36. Johnstone RW,. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002; 1: 287-99.
37. Iguchi H, Urashima Y, Inagaki Y, et al. SOX6 suppresses cyclin D1 promoter activity by interacting with beta-catenin and histone deacetylase 1, and its down-regulation induces pancreatic beta-cell proliferation. J Biol Chem 2007; 282: 19052-61.
38. Hematulin A, Sagan D, Eckardt-Schupp F, et al. NBS1 is required for IGF-1 induced cellular proliferation through the Ras/Raf/MEK/ERK cascade. Cell Signal 2008; 20: 2276-85.
39. Drews-Elger K, Ortells MC, Rao A, et al. The transcription factor NFAT5 is required for cyclin expression and cell cycle progression in cells exposed to hypertonic stress. PLoS One 2009; 4: e5245.